Hormonal
GLP-1 receptor agonist use is associated with an increased risk of hair loss (alopecia, telogen effluvium), with incidence potentially correlated with the magnitude of weight loss.
If you are using a GLP-1 agonist (like Ozempic or Mounjaro) and notice increased shedding or thinning, this is a known potential side effect, often linked to rapid weight loss or hormonal shifts. It does not happen to everyone, and in some cases, hair regrowth has been observed. Do not stop your medication abruptly without consulting your doctor; discuss monitoring strategies or temporary pauses if the hair loss is severe.
the FDA Adverse Event Reporting System (FAERS)... reported that GLP-1 RAs were the most common medications causing dermatological adverse events like hair loss
Why this rating
Based on a systematic review of mixed study designs (RCTs, retrospective, case reports) with conflicting findings.
Source
Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
Omar A Alsuwailem et al. · Cureus · 2025
DOI 10.7759/cureus.92454
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →